Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ASLN Stock Alerts

ASLAN Pharmaceuticals (ASLN) Competitors

ASLAN Pharmaceuticals logo
$0.60 0.00 (0.00%)
As of 05/14/2026
Compare

ASLN vs. SNYR, INDP, FBLG, ERNA, and QUCY

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? MarketBeat compares ASLAN Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ASLAN Pharmaceuticals include Synergy CHC (SNYR), Indaptus Therapeutics (INDP), FibroBiologics (FBLG), Ernexa Therapeutics (ERNA), and Mainz Biomed (QUCY). These companies are all part of the "pharmaceutical products" industry.

How does ASLAN Pharmaceuticals compare to Synergy CHC?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Synergy CHC's net margin of -42.59%. Synergy CHC's return on equity of -19.51% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Synergy CHC -42.59%-19.51%-5.29%

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Synergy CHC has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market.

In the previous week, Synergy CHC had 6 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 6 mentions for Synergy CHC and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 beat Synergy CHC's score of -0.11 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Synergy CHC Neutral

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 56.6% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Synergy CHC has higher revenue and earnings than ASLAN Pharmaceuticals. Synergy CHC is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Synergy CHC$30.38M0.14-$12.34M-$1.07N/A

Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 2,079.98%. Given Synergy CHC's stronger consensus rating and higher possible upside, analysts plainly believe Synergy CHC is more favorable than ASLAN Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Synergy CHC
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Synergy CHC beats ASLAN Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Indaptus Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Indaptus Therapeutics' return on equity of -939.67% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -939.67% -293.64%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

In the previous week, Indaptus Therapeutics had 3 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 3 mentions for Indaptus Therapeutics and 0 mentions for ASLAN Pharmaceuticals. Indaptus Therapeutics' average media sentiment score of 1.89 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Indaptus Therapeutics Very Positive
ASLAN Pharmaceuticals Neutral

Indaptus Therapeutics has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$24.13N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

Summary

Indaptus Therapeutics and ASLAN Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to FibroBiologics?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than ASLAN Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
FibroBiologics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

In the previous week, FibroBiologics had 5 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 5 mentions for FibroBiologics and 0 mentions for ASLAN Pharmaceuticals. FibroBiologics' average media sentiment score of 0.47 beat ASLAN Pharmaceuticals' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
FibroBiologics Neutral

FibroBiologics has lower revenue, but higher earnings than ASLAN Pharmaceuticals. FibroBiologics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
FibroBiologicsN/AN/A-$18.65M-$6.93N/A

FibroBiologics' return on equity of -767.07% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
FibroBiologics N/A -767.07%-195.56%

Summary

FibroBiologics beats ASLAN Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Ernexa Therapeutics?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Ernexa Therapeutics has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Ernexa Therapeutics$580K27.50-$14.08M-$26.20N/A

In the previous week, Ernexa Therapeutics had 27 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 27 mentions for Ernexa Therapeutics and 0 mentions for ASLAN Pharmaceuticals. Ernexa Therapeutics' average media sentiment score of 0.39 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Ernexa Therapeutics Neutral

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 120.10%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than ASLAN Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ernexa Therapeutics' return on equity of -263.74% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Ernexa Therapeutics N/A -263.74%-151.16%

Summary

Ernexa Therapeutics beats ASLAN Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Mainz Biomed's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 9.8% of Mainz Biomed shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mainz Biomed has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Mainz Biomed has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Mainz Biomed is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$540K80.22-$16.21M-$65.60N/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

In the previous week, Mainz Biomed had 15 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 15 mentions for Mainz Biomed and 0 mentions for ASLAN Pharmaceuticals. Mainz Biomed's average media sentiment score of 0.21 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the media.

Company Overall Sentiment
Mainz Biomed Neutral
ASLAN Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Mainz Biomed beats ASLAN Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASLN vs. The Competition

Export
MetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.23M$934.93M$6.23B$12.27B
Dividend YieldN/A4.84%2.80%5.35%
P/E Ratio-0.031.4820.1625.23
Price / Sales0.10116.45542.0173.12
Price / CashN/A20.0743.2656.33
Price / Book-0.098.309.816.90
Net Income-$44.22M-$3.77M$3.56B$333.88M
7 Day PerformanceN/A8.41%0.27%0.01%
1 Month PerformanceN/A61.16%-0.98%1.75%
1 Year PerformanceN/A117.62%36.22%32.67%

ASLAN Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat		N/AN/A$1.23M$12MN/A30
SNYR
Synergy CHC
3.8298 of 5 stars		$0.36
+10.8%		$6.25
+1,628.9%		-85.8%$4.86M$30.38MN/A40
INDP
Indaptus Therapeutics
0.8959 of 5 stars		$2.05
-1.9%		N/A-85.2%$4.69MN/AN/A6
FBLG
FibroBiologics
3.6303 of 5 stars		$1.29
-3.0%		$74.00
+5,636.4%		-93.5%$4.67MN/AN/A10
ERNA
Ernexa Therapeutics
3.1834 of 5 stars		$6.04
+51.4%		N/A-89.7%$4.65M$580KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel